Abbott Laboratories Draws Bullish Targets As Legal Overhang Eases

Abbott Laboratories stocks have been trading up by 10.84 percent following strong earnings and guidance that exceeded market expectations.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading ABT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For ABT Traders

Baird initiated coverage of Abbott with an Outperform rating and a $121 price target, pointing to 6%–8% sales growth and low double-digit earnings growth through 2028.
Citi’s sum-of-the-parts work pegs fair value for ABT at $99–$104 versus a prior ~$89 trading level, leaning on easing headwinds and a new product cycle.
Evercore ISI trimmed its ABT target to $112 from $120 but kept an Outperform rating, citing healthy MedTech and diagnostics trends into Q2.
Abbott signed a global licensing deal with ALZpath to build an Alzheimer’s blood test on its Alinity systems, expanding its diagnostics pipeline.
The U.S. Department of Justice ended its years-long baby formula probe with no criminal charges, shifting to a civil settlement over federal nutrition-program funds.

Quick Financial Overview

ABT has quietly put together a constructive tape. Over the past several sessions, Abbott Laboratories climbed from the high $80s to close near $98.97 on 2026/07/16, breaking out above the low‑$90s range that capped it earlier in the month. That kind of multi‑day push, with higher lows from 2026/07/01 onward, tells traders demand is stepping in on dips.

Intraday action backs that up. On the latest session, ABT opened strong near $95.29 and pushed as high as $101.87 before settling just under $99. The five‑minute chart shows tight, controlled intraday swings around $99–$100 for most of the afternoon — not a wild momentum name, but steady institutional‑style buying.

More Breaking News

Fundamentals line up with that tone. Abbott Laboratories generated about $44.33B in annual revenue, with a healthy 56.3% gross margin and roughly 19.2% EBIT margin. A price/earnings ratio around 25.4 and price/sales near 3.5 place ABT in quality MedTech territory, not deep value but not bubble either. Returns on equity above 18% and manageable leverage (total debt-to-equity around 0.65) show ABT is using its balance sheet, not abusing it. For traders, this is a steady compounder where news and sentiment, not survival risk, drive the swings.

Why Traders Are Watching ABT Now

What has ABT back on screens is the combination of bullish analyst calls, new products, and a fading legal cloud.

On the Street side, Baird just initiated coverage of Abbott Laboratories with an Outperform rating and a $121 price target, well above where ABT has been trading. They are modeling 6%–8% annual sales growth and low double‑digit earnings growth, helped by new products and synergies with Exact Sciences through 2027–2028. That is a multi‑year growth script, not just a one‑quarter pop. A fresh Outperform initiation with a target north of $120 often acts as a sentiment spark, especially when the chart is already trending up.

Citi adds more fuel. Its sum‑of‑the‑parts work puts fair value for ABT around $99–$104 per share, versus the earlier ~$89 area. The key drivers: easing headwinds and a new product cycle across MedTech and diagnostics. For traders, that means big‑cap money managers have a clear “buy the dips” valuation anchor in the high $90s.

Even Evercore ISI, while trimming its ABT target to $112 from $120, stayed in the Outperform camp. They cite healthy procedure volumes and capital spending in MedTech, life sciences tools, and diagnostics into Q2. That sounds more like fine‑tuning than bailing out, and it keeps Abbott Laboratories in the market’s “quality growth” bucket.

On the innovation front, ABT’s licensing deal with ALZpath to use the pTau217 antibody to build a blood‑based Alzheimer’s test on its Alinity ci‑series is strategically big. Abbott Laboratories already has a massive installed Alinity base in labs worldwide. Plugging a new high‑value assay like an Alzheimer’s blood test onto that hardware can scale fast if clinical adoption is strong. Traders who follow MedTech know that one successful platform assay can drive years of incremental revenue.

At the same time, a major overhang is shifting. The U.S. Department of Justice closed its years‑long investigation into Abbott’s baby formula operations with no criminal charges, moving instead toward a civil False Claims Act settlement. Headlines still remind the market of the serious infant formula episode, but the removal of criminal risk lowers the tail‑risk scenario that had been hanging over ABT. Short term, shares dipped on the news as traders digested the civil angle. Longer term, many will treat this as a de‑risking step, especially as Abbott Laboratories pushes its Similac “Love Without Measure” campaign to rebuild trust with young parents.

Layer in expected benefits from CMS’s proposed TAVR coverage expansion, which supports ABT’s structural heart franchise, and you get a picture of a MedTech name with multiple tailwinds just as the chart turns up.

Conclusion

Right now, ABT sits at the crossroads of solid fundamentals, cleaner headlines, and a bullish Street narrative. Abbott Laboratories is not a tiny low‑float flyer; it is a $40B‑plus revenue machine with 56% gross margins and double‑digit returns on capital. That kind of base lets news — analyst calls, product deals, regulatory shifts — move the stock without traders worrying about existential risk.

For short‑term traders, the recent run from the high $80s to the high $90s matters. ABT has shown it can spike intraday above $100 and still close strong, which sets up clear levels to trade around: support in the low‑to‑mid $90s, resistance near the low $100s. When multiple firms like Baird, Citi, and Evercore ISI cluster price targets between roughly $99 and $121, pullbacks toward the lower end of that band tend to attract dip‑buyers. In this kind of setup, disciplined tracking of how ABT behaves around these levels can sharpen a trader’s edge — and, as Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.” — making each ABT trade part of a broader trading education.

The big wild card is Q2 earnings, scheduled for release on 2026/07/16. That is the next checkpoint where Abbott Laboratories has to prove that procedure strength, diagnostics momentum, and product launches are converting into the 6%–8% growth the Street is modeling — and that the baby formula saga is financially contained. As Tim Sykes loves to remind traders, “The market doesn’t reward what you hope for, it rewards what you can prove on the chart and in the numbers.” ABT’s numbers and tape are finally lining up; now traders will see if the follow‑through is real.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!